Losartan Potassium Tablet, Film Coated
Product Images NDC 51655-418

6 FDA label images from Northwind Health Company, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 51655-418). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image001 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 01)

Image001 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 01)
Chemical structure diagram of the active ingredient Losartan Potassium showing multiple ring structures, including a chlorinated pyrimidine ring, a biphenyl group, and a potassium ion (K+).*
FDA Label Image

Image002 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 02)

Image002 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 02)
A line graph comparing the percentage of patients with a primary endpoint over study months for Atenolol (dotted line) versus Losartan potassium (solid line). The x-axis shows study months up to 66, and the y-axis shows the percentage of patients up to 16%. The graph notes an adjusted risk reduction of 13%, with a p-value of 0.021.*
FDA Label Image

Image003 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 03)

Image003 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 03)
A line graph depicting the percentage of patients with fatal/non-fatal stroke over study months up to 66 months, comparing atenolol (dotted line) and losartan potassium (solid line). The graph shows adjusted risk reduction of 25% for losartan potassium versus atenolol with a p-value of 0.001.*
FDA Label Image

Image004 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 04)

Image004 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 04)
A forest plot chart comparing event rates and hazard ratios between Losartan Potassium and Atenolol for primary composite outcomes and stroke outcomes, categorized by age, gender, race, ISH, diabetes, and history of cardiovascular disease. The horizontal axis shows hazard ratios with indicators favoring either Losartan Potassium or Atenolol.*
FDA Label Image

Image005 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 05)

Image005 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 05)
A line chart showing the percentage of patients with events over 48 months comparing Losartan potassium and placebo. The chart indicates a risk reduction of 16.1% associated with Losartan potassium, with patient event rates plotted over time from 0 to 48 months.*
FDA Label Image

Label (51655 418 26 Rev A 07 20 Nhc)

Label (51655 418 26   Rev A 07 20 Nhc)
Label for Losartan Potassium Tablets, USP 50 mg, displaying a quantity of 90 tablets for prescription use only. It provides storage instructions and notes that each tablet contains 50 mg of Losartan Potassium. The product is labeled by Northwind Health Company, LLC, with NDC 51655-418-26. Additional details include lot number, expiration date, and packaging information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.